Evidence map›Paper›PMID 29400663›Full record

ArticleCancer biomarkers : section A of Disease markers2018

Clusterin promotes growth and invasion of clear cell renal carcinoma cell by upregulation of S100A4 expression.

Yuan Liu, Changping Men, Yingmin Xu, Kai Zhao, Lei Luo, Dahai Dong, Qinchao Yu

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Biomarkers of tumor invasiveness in proteomics (Review).International journal of oncology · 2020
    Pooled it
  2. Review
  3. The role and function of CLU in cancer biology and therapy.Clinical and experimental medicine · 2023
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yuan LiuDepartment of Urology, The Central Hospital of Linyi, Yishui, Shandong, China.
Changping MenDepartment of Urology, Yantai Yuhuangding Hospital, Yantai, Shandong, China.
Yingmin XuDepartment of Urology, The Central Hospital of Linyi, Yishui, Shandong, China.
Kai ZhaoDepartment of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Lei LuoDepartment of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Dahai DongDepartment of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Qinchao YuDepartment of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Qingdao University · CNLinyi People's Hospital · CNYuhuangding Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveClusterin promotes cell proliferation, motility and invasiveness in human renal cell carcinoma (RCC) cells but the underlying molecular mechanisms of this action are largely unknown. The aim of this study was to investigate the effects of clusterin on cancer cell growth, invasion and S100A4 expression and to determine the effects of clusterin on in vitro cell proliferation and migration and in vivo tumour growth in RCC cells.

methodsWe have established stable transfectants of highly invasive Caki-1 human RCC cells with expression of clusterin shRNA targeting clusterin (Caki-1/clusterin shRNA). We also established stable transfectants of 786-O human RCC cells with expression of clusterin cDNA plaismid (786-O/clusterin cDNA). Clusterin and S100A4 expression was detected by reverse transcription (RT) PCR and western blot assay; Caki-1/clusterin shRNA and 786-O/clusterin cDNA clones were subjected to in vitro-invasion assays. Cell viability and cell growth was assessed in MTT and clonogenic assay. Specific small interfering RNA was employed to down-regulate S100A4. The expression plasmid for S100A4 (pCMV-S100A4) was used to upregulate S100A4. Caki-1/clusterin shRNA clones were injected subcutaneously in nude mice to determine tumour growth and cancer cell invasiveness in vivo. Xenograft tumour tissues were assessed by immunohistochemistry and frozen tissues were used for the detection of S100A4 and clusterin.

resultsOverexpression of clusterin increased cell invasiveness; and targeting clusterin reduced cell invasiveness in vitro. This increase in cell invasiveness was mediated by S100A4. Targeting clusterin decreased cell proliferation and down-regulated cellular S100A4 levels in Caki-1 cells; Overexpression of clusterin increased cell proliferation and up-regulated cellular S100A4 levels in 786-O cells; Stable Caki-1/clusterin shRNA transfectants produced smaller xenograft tumours containing reduced S100A4 protein levels in vivo. Stable 786-O/clusterin cDNA transfectants produced larger xenograft tumours containing increased S100A4 protein levels in vivo.

conclusionOur results indicate that clusterin promotes growth and invasion in RCC cells in vitro and in vivo through upregulation of S100A4; And targeting clusterin confers growth inhibitory and anti-invasive properties in RCC cells in vitro and in vivo through a down-regulation of S100A4. These findings provide the rationale for future oncostatic strategies aimed at suppressing clusterin-mediated signal transduction pathways as a novel therapeutic approach in human RCC.

Indexed as

AnimalsCarcinoma, Renal CellCell Line, TumorCell ProliferationClusterinGene Expression Regulation, NeoplasticHeterograftsHumansKidney NeoplasmsMiceMice, NudeNeoplasm InvasivenessS100 Calcium-Binding Protein A4Up-RegulationCLU protein, humanClusterinS100A4 protein, humanS100 Calcium-Binding Protein A4clusteringrowthinvasionRenal cell carcinomaS100a4

Identifiers

PMID29400663
PMCPMC13078326
OpenAlexW2787304843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.